CIK 0001671858 · Non-accelerated filer<br>Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811489190
- Phone
- 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-12 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −4,876 | $17.64 | $86K | 1,248,499 |
| 2024-11-12 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −45,045 | $16.76 | $755K | 1,301,449 |
| 2024-11-12 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −4,955 | $17.64 | $87K | 1,296,494 |
| 2024-11-12 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −45,124 | $16.76 | $756K | 1,253,375 |
| 2024-11-12 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −4,876 | $17.64 | $86K | 1,248,499 |
| 2024-11-12 | Flynn James E 10% owner | Sale | −7,853 | $17.16 | $135K | 5,266,883 |
| 2024-11-12 | Flynn James E 10% owner | Sale | −7,854 | $17.16 | $135K | 5,266,881 |
| 2024-11-12 | Flynn James E 10% owner | Sale | −9,554 | $17.77 | $170K | 5,257,329 |
| 2024-11-12 | Flynn James E 10% owner | Sale | −9,553 | $17.77 | $170K | 5,257,328 |
| 2024-11-11 | Flynn James E 10% owner | Sale | −40,596 | $17.45 | $708K | 5,498,368 |
| 2024-11-11 | Flynn James E 10% owner | Sale | −40,596 | $17.45 | $708K | 5,498,367 |
| 2024-11-11 | Flynn James E 10% owner | Sale | −223,632 | $18.15 | $4.1M | 5,274,736 |
| 2024-11-11 | Flynn James E 10% owner | Sale | −223,632 | $18.15 | $4.1M | 5,274,735 |
| 2024-10-16 | Scott Kathleen D. Chief Financial Officer | Option exercise 10b5-1 | +12,500 | $1.50 | $19K | 17,449 |
| 2024-10-16 | Scott Kathleen D. Chief Financial Officer | Sale 10b5-1 | −12,500 | $16.00 | $200K | 4,949 |
| 2024-10-16 | Scott Kathleen D. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,500 | 802,330 | ||
| 2024-10-15 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −48,550 | $14.86 | $722K | 1,398,897 |
| 2024-10-15 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,450 | $15.25 | $22K | 1,397,447 |
| 2024-10-15 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −50,000 | $14.88 | $744K | 1,298,499 |
| 2024-10-15 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −48,550 | $14.86 | $722K | 1,398,897 |
Page 10 of 14 · 267 trades